KAPA Kairos Pharma, Ltd.
$0.52▼ -1.30%
Healthcare
Other
After hours
$0.54▲ +2.80%
Oct 28, 6:05 PM ET
Volume 65.0K
Avg Volume (10D) 152.0K
Key Metrics & Fundamentals
Market Cap
$1.77M
P/E Ratio
–
Div Yield
0.00%
52W Range
0.52 - 8.12
% vs 50 MA
-62.34%
% vs 200 MA
-83.12%
RSI-14
18.1
MACD Histogram
+0.0100
Beta (1Y vs SPY)
1.64
Free Cash Flow
-$1.01M
Gross Rev
$0
Gross Profit
$0
EBITDA
-$1.40M
COGS
–
Operating Exp
$1.42M
Operating Income
-$1.42M
EBIT
-$1.42M
Pretax Income
-$1.39M
Net Income
-$1.39M
EPS (Diluted)
-0.06
Price & Volume History
Loading chart…
Recent News
CEO.CA's Inside the Boardroom: Major U.S. Cancer Centers Are Testing This New Drug: Kairos Pharma
TMX Newsfile · Oct 22, 2026 9:16 AM ET
Kairos Pharma Reports Positive, Statistically Significant Interim Efficacy Data from Phase 2 Trial of ENV-105 in Metastatic Prostate Cancer
Business Wire · Oct 6, 2026 7:30 AM ET
Kairos Pharma to Present and Moderate at Discovery on Target Conference in Boston, MA
Business Wire · Sep 23, 2026 8:00 AM ET
Kairos Pharma to Present at the H.C. Wainwright 28th Annual Global Investment Conference
Business Wire · Sep 9, 2026 8:00 AM ET
Kairos Pharma to Conduct 1-for-7 Reverse Stock Split
MT Newswires · Aug 21, 2026 4:45 PM ET
Kairos Pharma Announces 1-for-7 Reverse Stock Split
Business Wire · Aug 21, 2026 4:30 PM ET
Bayer (XTRA:BAYN) Stock Still Looks Reasonable On New Prostate Cancer News
Simply Wall St. · Aug 4, 2026 10:12 AM ET
Financial Overview - Income Statement
Quarterly
No financial data available. Click Refresh on the ticker to load latest fundamentals.
See KAPA's money flow as a full page
Social Sentiment
Loading Reddit posts…
AI Analysis
Click Generate Analysis for an AI-powered summary, bull & bear case, and recent performance review.
Not financial advice.
All data, scores, charts, and analysis on this site are provided for informational and educational
purposes only and do not constitute financial, investment, legal, or tax advice.
Past performance is not indicative of future results.
See our Legal Notice for full details.